NICE: AstraZeneca's Faslodex in breast cancer not 'a good use of resources'
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is poised to reject AstraZeneca's Faslodex (fulvestrant) 500mg as an alternative to aromatase inhibitors for treating some women with breast cancer. The institute said there was too much uncertainty over the drug for it to be "a good use of NHS resources".